PI-RADS第2版:在前列腺穿刺Gleason评分6分患者中检测临床显著癌
研究纳入182例穿刺证实Gleason评分6分的前列腺癌患者,术前行MRI并由3名独立阅片者按PI-RADSv2评分,以根治性前列腺切除标本定义临床显著癌。临床显著癌占87.4%(159/182);有经验阅片者1和2的cutoff为4分,AUC分别为0.829和0.853(p<0.001),经验不足阅片者3的cutoff为5分,AUC为0.602(p=0.067)。作者认为PI-RADSv2可能帮助有经验阅片者识别临床显著癌,但部分小于1 cm3的临床显著癌可能被漏诊。
要点
- 穿刺Gleason评分6分患者中,手术证实临床显著癌占87.4%(159/182)。
- 有经验阅片者以PI-RADSv2评分4分为cutoff,AUC分别为0.829和0.853(p<0.001)。
- 经验不足阅片者以5分为cutoff,AUC为0.602(p=0.067)。
核心结论
- PI-RADSv2可能帮助有经验阅片者识别穿刺Gleason评分6分患者的临床显著前列腺癌,但部分小于1 cm3的临床显著癌可能被漏诊。
研究设计与样本
- 研究纳入182例连续登记、穿刺证实Gleason评分6分的前列腺癌患者,均行MRI和根治性前列腺切除术。
诊断标准与关键数值
- 临床显著癌的手术定义:Gleason评分≥7分,或肿瘤体积≥0.5 cm3,或肿瘤分期≥T3。
- 有经验阅片者1和2的PI-RADSv2 cutoff为4分,AUC分别为0.829和0.853(p<0.001)。
- 经验不足阅片者3的PI-RADSv2 cutoff为5分,AUC为0.602(p=0.067)。
- 阅片者1:敏感度89.9%(143/159),特异度69.6%(16/23),阳性预测值95.3%(143/150),阴性预测值50.0%(16/32),准确率87.4%(159/182)。
- 阅片者2:敏感度81.1%(129/159),特异度82.6%(19/23),阳性预测值97.0%(129/133),阴性预测值38.8%(19/49),准确率81.3%(148/182)。
临床应用与阅片要点
- 在有经验阅片者中,以PI-RADSv2评分4分为cutoff时,阅片者1敏感度89.9%(143/159)、特异度69.6%(16/23),阅片者2敏感度81.1%(129/159)、特异度82.6%(19/23)。
- 对有经验阅片者的假阴性病例,66.7%–81.3%的临床显著癌肿瘤体积小于1 cm3。
局限性
- 使用PI-RADSv2时,部分小于1 cm3的临床显著癌可能被漏诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this study was to analyze the utility of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) in the detection of a clinically significant cancers in patients with prostate cancers with a biopsy Gleason score of 6.
MATERIALS AND METHODS: A group of 182 consecutively registered patients with biopsy-proven prostate cancer with a Gleason score of 6 underwent MRI and radical prostatectomy. Clinically significant cancer was surgically defined as Gleason score of 7 or greater, tumor volume of 0.5 cm3 or greater, or tumor category T3 or greater. Clinical parameters (prostate-specific antigen level, greatest percentage of biopsy core, and percentage of positive cores) and the PI-RADSv2 ratings by three independent readers (experienced readers 1 and 2, inexperienced reader 3) were investigated. Cutoffs and the diagnostic performance of PI-RADSv2 for clinically significant cancer were analyzed.
RESULTS: Clinically significant cancer was found in 87.4% (159/182) of patients. The cutoff PI-RADSv2 score for clinically significant cancer was 4 for readers 1 and 2 and 5 for reader 3. The AUCs were 0.829 and 0.853 for readers 1 and 2 (p < 0.001) and 0.602 for reader 3 (p = 0.067). For reader 1, sensitivity was 89.9% (143/159); specificity, 69.6% (16/23); positive predictive value, 95.3% (143/150); negative predictive value, 50.0% (16/32); and accuracy, 87.4% (159/182). The corresponding values for reader 2 were 81.1% (129/159), 82.6% (19/23), 97.0% (129/133), 38.8% (19/49), and 81.3% (148/182). For the experienced readers, 66.7-81.3% of patients with false-negative results had clinically significant cancers with tumor volume less than 1 cm3.
CONCLUSION: PI-RADSv2 may help experienced readers identify clinically significant prostate cancers in patients with a biopsy Gleason score of 6. However, some small (< 1 cm3) clinically significant cancers can be missed when PI-RADSv2 is used.
引用
- Seo JW, Shin SJ, Taik Oh Y, et al. PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer. AJR Am J Roentgenol. 2017. PMID: 28418690. doi:10.2214/AJR.16.16981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。